The challenge of defining "ultra-high-risk" neuroblastoma
- 31 March 2019
- journal article
- review article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 66 (4), e27556
- https://doi.org/10.1002/pbc.27556
Abstract
Given the biological and clinical heterogeneity of neuroblastoma, risk stratification is vital to determining appropriate treatment. Historically, most patients with high-risk neuroblastoma (HR-NBL) have been treated uniformly without further stratification. Attempts have been made to identify factors that can be used to risk stratify these patients and to characterize an "ultra-high-risk" (UHR) subpopulation with particularly poor outcome. However, among published data, there is a lack of consensus in the definition of the UHR population and heterogeneity in the endpoints and statistical methods used. This review summarizes our current understanding of stratification of HR-NBL and discusses the complex issues in defining UHR neuroblastoma.Keywords
This publication has 72 references indexed in Scilit:
- Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplificationProceedings of the National Academy of Sciences of the United States of America, 2012
- Association of Age at Diagnosis and Genetic Mutations in Patients With NeuroblastomaJama-Journal Of The American Medical Association, 2012
- Clinical and Biologic Features Predictive of Survival After Relapse of Neuroblastoma: A Report From the International Neuroblastoma Risk Group ProjectJournal of Clinical Oncology, 2011
- Challenging issues in pediatric oncologyNature Reviews Clinical Oncology, 2011
- Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for NeuroblastomaNew England Journal of Medicine, 2010
- A biology-driven approach identifies the hypoxia gene signature as a predictor of the outcome of neuroblastoma patientsMolecular Cancer, 2010
- Mutation-Independent Anaplastic Lymphoma Kinase Overexpression in Poor Prognosis Neuroblastoma PatientsCancer Research, 2009
- Prognostic Significance of Interleukin-6 Single Nucleotide Polymorphism Genotypes in Neuroblastoma:rs1800795(Promoter) andrs8192284(Receptor)Clinical Cancer Research, 2009
- Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH studyThe Lancet Oncology, 2009
- The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force ReportJournal of Clinical Oncology, 2009